IRE-1α inhibitors

Patent metadata

Field	Value
Publication number	US-9546149-B2
Application number	US-201514969837-A
Country	US
Kind code	B2
Filing date	Dec 15, 2015
Priority date	Jun 8, 2007
Publication date	Jan 17, 2017
Grant date	Jan 17, 2017

Abstract

Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.

First claim

The invention claimed is:

1. A compound or a pharmaceutically acceptable salt thereof, which falls within structural formula (A2):

wherein:
R 1 is hydrogen, halogen, or a 5- or 6-membered heterocyclic containing one or two heteroatoms independently selected from nitrogen, oxygen, and sulfur;
R 3 is hydrogen, halogen, —NO 2 , C 1 -C 3 linear or branched alkyl, C 1 -C 3 linear or branched alkoxy, C 1 -C 3 linear or branched hydroxyl alkyl,

 and
R 4 , R 5 , and R 6 are independently selected from

 C 1 -C 3 linear or branched alkyl,

 C 1 -C 3 phenylalkyl, C 1 -C 3 alkoxyphenylalkyl,

2. A compound or a pharmaceutically acceptable salt thereof, which falls within structural formula (A3):

wherein
R 1 is hydrogen;
R 3 is

 and
Q is selected from the group consisting of

3. A compound or a pharmaceutically acceptable salt thereof, which falls within the scope of formula (A4):

wherein:
R 1 is hydrogen;
R 3 is hydrogen, —F, —NO 2 , or

R 8 is

 or, together with R 9 and the nitrogen atom to which they are attached, is

 and
R 9 is hydrogen or, together with R 8 and the nitrogen atom to which they are attached, is

4. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

5. A pharmaceutical composition comprising a compound of claim 2 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

6. A pharmaceutical composition comprising a compound of claim 3 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Assignees

• Mannkind Corp

Inventors

• Patterson John B
• Lonergan David G
• Flynn Gary A
• Zeng Qingpeng
• Pallai Peter V

Classifications

• A61P37/02

  Immunomodulators · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P31/12

  Antivirals · CPC title